Ponsegromab for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 25 May 2025: Trial registered, NCT06989437
  2. 3 Oct 2025: Trial started, NCT06989437

The trials

NCT06989437: A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

State
Under way
Phase
Phase 2 and Phase 3
People
982 planned
Started
3 Oct 2025
Primary completion
23 Jan 2028
Arms
Double-Blind ponsegromab Treatment lower dose, Double-Blind ponsegromab Treatment higher dose
Results
None posted
  1. 25 May 2025: Trial registered
  2. 3 Oct 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.